Graeme Currie - Jul 3, 2023 Form 3 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Role
Chief Development Officer
Signature
/s/ Graeme Currie
Stock symbol
KTTA
Transactions as of
Jul 3, 2023
Transactions value $
$0
Form type
3
Date filed
7/3/2023, 05:00 PM
Next filing
Mar 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KTTA Stock Option (right to buy) Jul 3, 2023 Common Stock, par value $0.0001 per share 300K $0.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 33% of the shares underlying the option vest on June 30, 2023, and the remaining shares will vest in equal quarterly installments for each of the two years thereafter, in each case subject to the Reporting Person continuing to be employed or otherwise provide services to the Issuer on each vesting date.

Remarks:

Exhibit 24--Power of Attorney